Home

CENRIFKI is the first and only treatment to reduce the risk of disability progression in patients with nrSPMS^1,2

Every day counts to preserve abilities^3,4

A brain penetrant and bioactive BTKi^1,3,4

Dive deeper into the mechanism of action for CENRIFKI

BTKi=Bruton’s Tyrosine Kinase inhibitor; nrSPMS=non-relapsing secondary progressive multiple sclerosis.

API

References

1. Cenrifki UAE SMPC 2025 2. Fox RJ, Bar-Or A, Traboulsee A, et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. 2025;392(19):1883-1892. 3. Cree BAC, Hollenbach JA, Bove R, et al; University of California, San Francisco MS-EPIC Team. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653-666. 4. Frisch ES, Pretzsch R, Weber MS. A milestone in multiple sclerosis therapy: monoclonal antibodies against CD20–yet progress continues. Neurotherapeutics. 2021;18(3):1602-1622.

INDICATION

Cenrifki is a brain penetrant Bruton’s tyrosine kinase inhibitor (BTKi) indicated for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adults. (1)

IMPORTANT SAFETY INFORMATION

CENRIFKI can cause liver injury, which can lead to serious and fatal liver injury. Patients initiating and continuing treatment with CENRIFKI must have a baseline ALT, AST, alkaline phosphatase, and bilirubin measured before treatment initiation and regular monitoring during treatment. Concomitant use of CENRIFKI with other hepatotoxic drugs may increase the risk of severe liver injury. If drug induced liver injury (DILI) is suspected to be CENRIFKI-induced, discontinue treatment (2.1, 5.1) (1)

INDICATION

IMPORTANT SAFETY INFORMATION

CENRIFKI (tolebrutinib) is the first treatment approved for nrSPMS and to slow disability accumulation independent of relapse activity in adults1

CENRIFKI is the first and only treatment to reduce the risk of disability progression in patients with nrSPMS1,2

A brain penetrant and bioactive BTKi1,3,4

References

CENRIFKI(tolebrutinib) is the first treatment approved for nrSPMS and to slow disability accumulation independent of relapse activity in adults¹

CENRIFKI is the first and only treatment to reduce the risk of disability progression in patients with nrSPMS^1,2

A brain penetrant and bioactive BTKi^1,3,4